Tessék: https://www.reuters.com/business/healthcare-pharmaceuticals/uae-says-si…
Tests in the UAE suggested the vaccine was 86 per cent effective against preventing infection in Phase 3 trials involving 31,000 people. The manufacturer revised the figure to 79.34 per cent after it received more data.
Bővebben: https://en.wikipedia.org/wiki/BBIBP-CorV#Phase_III
On July 16, Sinopharm began conducting a Phase III vaccine trial of 31,000 volunteers in the UAE in collaboration with G42 Healthcare, an Abu Dhabi-based company.[26] By August, all volunteers had received their first dose and were to receive the second dose within the next few weeks.[27] On December 9, UAE's Ministry of Health and Prevention announced the official registration of BBICP-CorV, after an interim analysis of the Phase III trial showed BBIBP-CorV to have a 86% efficacy against COVID-19 infection.[28] The vaccine was 100% effectiveness in preventing moderate and severe cases of the disease.[29]